Traditional approaches have failed to address protein misfolding diseases. Wren is pioneering a new and radically different approach for drug discovery, driven by physical principles and based on decades of research from our scientific founders.
Total raised: $40.57M
Founded date: 2016
Investors 2
| Date | Name | Website |
| 26.08.2022 | Schooner C... | schoonerca... |
| - | Lifeforce ... | lifeforcec... |
Funding Rounds 2
| Date | Series | Amount | Investors |
| 25.01.2021 | - | $16.96M | - |
| 24.01.2019 | Series A | $23.62M | - |
Mentions in press and media 7
| Date | Title | Description |
| 25.01.2021 | Wren Therapeutics announces financing of £12.4 million | Wren Therapeutics Ltd, a biopharmaceutical company pioneering a unique network kinetics approach to drug discovery for protein misfolding diseases, today announced the closing of a £12.4 million (c. $17 million) financing. Wren is a spin-of... |
| 25.01.2021 | Wren Therapeutics Announces Financing of £12.4 Million (c. $17.0 Million) | Wren Therapeutics Ltd., (“Wren”), a biopharmaceutical company pioneering a unique network kinetics approach to drug discovery for protein misfolding diseases, today announced the closing of a £12.4 million (c. $17.0 million) financing. This... |
| 25.01.2021 | Wren Therapeutics announces financing of £12.4 million | Wren Therapeutics announces financing of £12.4 million 25-01-2021 Wren Therapeutics Ltd, a biopharmaceutical company pioneering a unique network kinetics approach to drug discovery for protein misfolding diseases, today announced the closin... |
| 01.12.2020 | Eisai and Wren Therapeutics enter into research collaboration agreement for drug discovery for synucleinopathies | Eisai and Wren Therapeutics enter into research collaboration agreement for drug discovery for synucleinopathies 01-12-2020 Eisai Co., Ltd (Tokyo) and Wren Therapeutics Ltd (Cambridge, UK) today announced that the companies have entered int... |
| 24.01.2019 | Term Sheet — Thursday, January 24 | HOLLYWOOD’S ODD COUPLE Good morning, Term Sheet readers. Paid Content Securing the enterprise without boundaries From ExtraHop As expected, Katzenberg boasted a star-studded list of investors backing the new venture. They include Disney, Al... |
| 24.01.2019 | Wren Therapeutics Completes £18M Series A Financing | Wren Therapeutics, a Cambridge, UK-based biopharmaceutical company focused on drug discovery and development for protein misfolding diseases, completed a £18m Series A financing round. The round was led by The Baupost Group with participati... |
| 23.01.2019 | Daily funding roundup - January 23nd, 2019 | AnChain.ai raised $2M; Chowbus raised $4M; Groww aised $6.2M; Anchorage raised $17 AnChain.ai: AnChain.ai is an AI powered blockchain ecosystem security. AnChain.ai has raised $2 million in seed funding led by AMINO Capital, with participat... |